How effective is HALAVEN® in the treatment of metastatic breast cancer (mBC)?

762 women

HALAVEN was compared with other chemotherapies or hormone
therapies commonly used to treat mBC.

In this study, 8 out of 10 women had breast cancer that had spread to other sites, including their lungs and/or liver.

women silo

Women who received HALAVEN lived, on average, 25% longer than women who received other chemotherapy or hormone therapy (13.2 months vs 10.6 months, respectively)

HALAVEN was studied in women with all types of tumor receptors. These receptors can be either positive or negative.

ER=estrogen receptor; PR=progesterone receptor; HER2/neu=human epidermal growth factor receptor 2.

clinical study of women with metastatic breast cancer